Amanote Research
Register
Sign In
Discover open access scientific publications
Search, annotate, share and cite publications
Publications by Inka Miñambres
Is There a Justification for Classifying GLP-1 Receptor Agonists as Basal and Prandial?
Diabetology and Metabolic Syndrome
Internal Medicine
Endocrinology
Metabolism
Diabetes
Related publications
Combination Therapy With GLP-1 Receptor Agonists and Basal Insulin: A Systematic Review of the Literature
Diabetes, Obesity and Metabolism
Internal Medicine
Endocrinology
Metabolism
Diabetes
The Cardiovascular Effects of GLP-1 Receptor Agonists
Cardiovascular Therapeutics
Medicine
Cardiovascular Medicine
Pharmacology
Cardiology
Cardiovascular Effects of Glucagon-Like Peptide 1 (GLP-1) Receptor Agonists
Cardiovascular Diabetology
Internal Medicine
Cardiology
Endocrinology
Cardiovascular Medicine
Metabolism
Diabetes
Extra Glycemic Impacts of GLP-1 Receptor Agonists: Benefits of a Class Effect?
Open Journal of Endocrine and Metabolic Diseases
Clinical Trial Highlights – GLP-1 Agonists
Journal of Parkinson's Disease
Molecular Neuroscience
Neurology
Cellular
Role and Development of GLP-1 Receptor Agonists in the Management of Diabetes
Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy
Internal Medicine
Pharmacology
Β-Arrestin-Biased Agonists of the GLP-1 Receptor From Β-Amino Acid Residue Incorporation Into GLP-1 Analogues
Journal of the American Chemical Society
Biochemistry
Colloid
Catalysis
Chemistry
Surface Chemistry
Correction To: Combining GLP-1 Receptor Agonists and Basal Insulin in Older Adults With Type 2 Diabetes: Focus on Lixisenatide and Insulin Glargine
Advances in Therapy
Medicine
Pharmacology
SGLT2 Inhibitors or GLP-1 Receptor Agonists as Second-Line Therapy in Type 2 Diabetes: Patient Selection and Perspectives
Vascular Health and Risk Management
